| abstract |
PROBLEM TO BE SOLVED: To provide adjuvant therapy including adjuvant cancer therapy, vaccination, and treatment of immune disorders and pathogenic infectious diseases. A pharmaceutical composition comprising an effective amount of a covalent TEC family kinase inhibitor for increasing the Th1: Th2 biomarker ratio in a subject having cancer. The cancer is characterized by a biomarker profile in which the Th1 response is suppressed and the Th2 response is enhanced. The amount of covalent TEC family kinase inhibitor is effective in reducing the Th2 response in the subject. Th2 biomarkers are selected from IL-10, IL-4, IL-13, Th1 biomarkers from IFN-γ, IL-2, IL-12, or combinations thereof. [Selection diagram] FIG. 1a |